Discover more on Bavarian Nordic's vaccine sales decline, diversification strategy, and strong Travel Health segment, ...

Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 ...

Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of ...

Bavarian Nordic has already secured a sizeable portion of revenue for 2025 through orders for its mpox/smallpox vaccine, but ...

Bavarian Nordic, a maker of the mpox vaccine, on Friday said the incoming Trump administration may present opportunities even ...

Bavarian Nordic A/S ( (BVNRY) ) has released its Q3 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its ...

Bavarian Nordic AS (BVNKF) reports robust travel health business growth and strategic advancements in vaccine launches amid ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Bavarian Nordic AS (OCSE:BAVA) is set to release its Q3 2024 earnings on Nov 15, 2024. The consensus estimate for Q3 2024 ...

European markets were set to open lower Friday, retreating from gains in the previous session, as investors pondered the future path for rate cuts.

COPENHAGEN, Denmark, November 15, 2024 – (OMX: BAVA) announced today its interim financial results for the first nine months ...

Current health news highlights include calls to reduce mpox test prices, CDC confirming Oregon's bird flu case, Eyenovia's ...